14:25 , Jun 29, 2018 |  BC Week In Review  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas Venture,...
11:27 , Jun 25, 2018 |  BC Extra  |  Financial News

NASH play Akero emerges from stealth with $65M

Investors in a $65 million series A round for Akero Therapeutics Inc. (Cambridge, Mass.) believe the company's newly acquired, Phase II-ready asset could best other therapies in efficacy to treat non-alcoholic steatohepatitis. New investors Atlas Venture,...
19:58 , Sep 21, 2017 |  BC Innovations  |  Targets & Mechanisms

Appetite for GFRAL

Simultaneous publications from Eli Lilly and Co., Johnson & Johnson and Novo Nordisk A/S identifying GFRAL as the receptor of the anti-obesity hormone GDF15 will undoubtedly accelerate therapeutic translation of the pathway. The race is...
18:04 , Aug 29, 2017 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Nerve damage Mouse studies suggest FGF21 could help treat spinal cord damage associated with traumatic brain injury (TBI) and multiple sclerosis. In postmortem tissue samples from MS patients, levels of the FGF21 signaling marker klotho...
14:37 , Apr 28, 2017 |  BC Week In Review  |  Clinical News

BMS-986036: Additional Ph II data

Additional data from a double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 for 16 weeks...
02:34 , Apr 24, 2017 |  BC Extra  |  Clinical News

NGM, BMS add to NASH data

Newly released data from a Phase II study of NGM282 from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) to treat non-alcoholic steatohepatitis showed that 3 and 6 mg doses of the candidate increased LDL levels...
23:33 , Apr 14, 2017 |  BioCentury  |  Product Development

New endpoints in NASH

Data on mid-stage NASH candidates to be presented at the European Association for the Study of the Liver’s International Liver Congress this month won’t enable solid comparisons with each other or with more advanced programs....
19:18 , Apr 7, 2017 |  BC Week In Review  |  Clinical News

BMS-986036: Ph II data

A double-blind, U.S. Phase II trial in 68 evaluable NASH patients with a hepatic fat fraction of ≥10% showed that once-daily 10 mg and once-weekly 20 mg subcutaneous BMS-986036 each met the primary endpoint of...
22:41 , Apr 5, 2017 |  BC Extra  |  Clinical News

New NASH readouts for NGM, Bristol

New data showed that fibroblast growth factor (FGF) analogs from NGM Biopharmaceuticals Inc. (South San Francisco, Calif.) and Bristol-Myers Squibb Co. (NYSE:BMY) each reduced liver fat in separate Phase II studies to treat non-alcoholic steatohepatitis....
00:41 , Mar 25, 2017 |  BioCentury  |  Strategy

Mountain climbing

U.S. pricing pressure on insulin and hemophilia products have caused Novo Nordisk A/S to guide for negative sales and operating profit growth for the first time ever. While newly launched diabetes and obesity products are...